NeuroHealing Pharmaceuticals Inc., of Newton, Mass., entered a strategic master services and investment deal with Cato BioVentures, which includes a collaboration with Cato Research Ltd., its contract research organization, to assist in the clinical development of NeuroHealing's lead drug NH001.